Bigul

Medico Intercontinental Ltd - 539938 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayMedico Intercontinental Ltd 2CINL24100GJ1984PLC111413 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 7.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PUNEETA SHARMA Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: mail@medicointercontinental.com Name of the Chief Financial Officer: JAY SHARADKUMAR SHAH Designation: CHIEF FINANCIAL OFFICER EmailId: mail@medicointercontinental.com Date: 07/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
07-04-2022
Bigul

Medico Intercontinental Ltd - 539938 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Dear Sir / Ma'am, We are enclosing herewith the Confirmation Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2022. Kindly take the above on your record.
02-04-2022
Bigul

Medico Intercontinental Ltd - 539938 - Statement Of Investor Complaints For The Quarter Ended March 2022

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Puneeta SharmaDesignation :- Company Secretary and Compliance Officer
02-04-2022
Bigul

Medico Intercontinental Ltd - 539938 - Closure of Trading Window

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and in compliance with circular no. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE Limited, we wish to inform you that the 'Trading Window' for dealing in the securities of the Company has been closed and shall remain closed for all the designated persons and their immediate relatives till the conclusion of 48 hours after the declaration of financial results of the company for the quarter and financial year ended March 31, 2022. Accordingly, all designated persons and their immediate relatives of the Company have been advised not to trade in the securities of the Company during the aforesaid period of closure of trading window. You are requested to disseminate the above information on your website.
31-03-2022
Bigul

Medico Intercontinental Ltd - 539938 - Announcement under Regulation 30 (LODR)-Resignation of Director

Dear Sir/Madam, With reference to abovementioned subject, we hereby inform you that Mr. Hiren Ravindrabhai Shah has resigned as an Independent Director of the Company w.e.f. 30th March, 2022. Pursuant to Regulation 30 (7A), we hereby confirm that there is no material reason for his resignation, other than those provided in the attached resignation letter. Kindly take the same on record.
30-03-2022
Bigul

Medico Intercontinental Ltd - 539938 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Dear Sir / Ma'am, We hereby wish to inform you that the Unaudited financial results (Standalone & Consolidated) for the quarter and nine months ended 31st December, 2021 were approved at the meeting of Board of Directors held on Monday, 14th February, 2022. In continuation to the same, the newspaper clipping duly published in English and Gujarati Newspaper is enclosed herewith. This is for your information and records.
15-02-2022
Bigul

Medico Intercontinental Ltd - 539938 - Results - Financial Results For The Quarter And Nine Months Ended 31/12/2021

Dear Sir/Ma'am, Pursuant to provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., February 14, 2022, inter alia, considered and approved unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended on December 31, 2021 along with Limited Review Report issued by M/s. V Goswami & Co, Chartered Accountants, Ahmedabad, Statutory Auditors of the Company. Further, please find enclosed 'Standalone and Consolidated Unaudited Financial Results,' for the quarter and nine months ended on December 31, 2021 and same is also available on the website of the Company viz. www.medicointercontinental.com The Board Meeting of the Company commenced at 12:30 P.M. and concluded at 04:10 P.M.
14-02-2022
Bigul

Medico Intercontinental Ltd - 539938 - Board Meeting Intimation for Board Meeting In Compliance Of Regulation 29, 30 And 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Medico Intercontinental Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2022 ,inter alia, to consider and approve With reference to the captioned subject, we wish to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Monday, 14th February, 2022 at the registered office of the Company situated at 1-5th Floor, Aditraj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad, Gujarat - 380015, to inter alia consider, approve and take on record the unaudited Financial Results (Standalone and Consolidated) for quarter and nine months ended 31st December, 2021 and any other business items as per agenda circulated.
07-02-2022
Bigul

Medico Intercontinental Ltd - 539938 - Reply To The Clarification Sought By Stock Exchange

Dear Sir, With reference to your email dated 03/02/2022, we wish to inform you that the Company has made all the necessary disclosures pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and has not withheld any material information/event that in our opinion would have bearing on the price/volume behavior of the scrip. The Company shall continue to make applicable disclosures, within the stipulated time. Therefore, the increase in the share price / volume of the company is purely due to market conditions and absolutely market driven and the management of the company is in no way connected with any such increase in price / volume. You are requested to take the same on record.
04-02-2022
Bigul

Medico Intercontinental Ltd - 539938 - Clarification sought from Medico Intercontinental Ltd

The Exchange has sought clarification from Medico Intercontinental Ltd on February 3, 2022 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.
04-02-2022
Next Page
Close

Let's Open Free Demat Account